<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190020</url>
  </required_header>
  <id_info>
    <org_study_id>MS-LUB-106</org_study_id>
    <nct_id>NCT01190020</nct_id>
  </id_info>
  <brief_title>Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.</brief_title>
  <official_title>Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lubiprostone, a chloride channel activator, has been shown to improve symptoms of chronic
      constipation, largely by enhancing chloride-rich intestinal fluid secretion. Whether
      Lubiprostone has effects on colonic methanogenesis is not known. The investigators
      hypothesize that the effects of Lubiprostone may in part be due to its effects on altering
      colonic flora, particularly methanogenic flora.

      By altering the colonic stasis of stool and through more efficient clearance of digestive
      residue, the investigators anticipate that Lubiprostone may either inhibit or promote better
      excretion of methanogenic flora, and thereby decrease the gut load of methane producing
      bacteria. In turn, this may lead to enhanced colonic smooth muscle contraction and an
      increased rate of spontaneous bowel movements and reduction of constipation symptoms.

      The aim is to investigate the effects of Lubiprostone on intestinal methane production and
      bowel symptoms in patients with chronic constipation, by performing a randomized, double
      blind, placebo controlled study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Methane Production</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>Change in the mean area under the curve of the breath hydrogen and methane gas profiles in parts per million, from time 0 to 120 minutes, between baseline versus mean area under the curve at the end of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool Frequency (Complete Spontaneous Bowel Movements)</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>change in mean stool frequency (delta) between baseline week and final week of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in the Colonic Transit Time</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>Percentage change of colonic transit time between the baseline colonic transit study and the colonic transit study at the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Methane Value</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>The peak methane value measured during the baseline breath study will be compared with the peak methane obtained at the end of study breath test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Chronic Constipation, Methanogenesis</condition>
  <arm_group>
    <arm_group_label>Lubiprostone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24mcg BID for 4 weeks, oral medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>24mcg BID for 4 weeks (placebo), oral medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone</intervention_name>
    <description>Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.</description>
    <arm_group_label>Lubiprostone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone Control</intervention_name>
    <description>Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Constipation as defined by Rome III criteria13. Patients must have symptoms &gt; 3
             days/month for the past three months and report at least two of the following symptoms
             ≥ 25% of the time: straining, lumpy or hard stool, sensation of incomplete evacuation,
             sensation of anorectal obstruction/blockage, use of manual maneuvers, &lt; 3 bowel
             movements/week. Also,they should have insufficient criteria for IBS, and only rarely
             loose stools without the use of laxatives.

          -  ≥ 3 ppm methane value at baseline1, 2(before sugar load).

        Exclusion Criteria:

          -  Patients taking drugs that are known to be constipating will be excluded or asked to
             discontinue medications for at least 2 weeks and reassessed. For example, we will
             recommend that patients taking calcium channel antagonists contact their respective
             primary care physicians to explore alternative medications for hypertension such as
             beta blockers or ACE-inhibitors. If the calcium channel antagonists are able to be
             discontinued, patients will be re-screened at least two weeks after the medications
             are discontinued. If patients no longer meet inclusion criteria, they will be excluded
             from the study. Patients who remain constipated will be eligible for enrollment.

          -  Patients with co-morbid illnesses such as severe cardiovascular disease, chronic renal
             failure, or those with previous gastrointestinal surgery except cholecystectomy and
             appendectomy

          -  Patients with neurologic diseases such as multiple sclerosis, strokes, spinal cord
             injuries, and those who have problems with cognizance, i.e. a mini-mental score of &lt;15
             and/or are legally blind will be excluded.

          -  Women who are pregnant or are likely to conceive during the course of the study will
             be excluded. Urinary pregnancy tests will be performed on all women of child-bearing
             potential prior to enrollment and before any x-ray of the abdomen.

          -  Patients with Hirschsprung' s disease, or active local anorectal problems such as anal
             fissures, bleeding hemorrhoids, Crohn's, colitis, or colon cancer.

          -  Patients with alternating constipation and diarrhea and those who fulfill the Rome-III
             criteria for irritable bowel syndrome.

          -  Recent antibiotic use (last 6 weeks).

          -  Patients using laxatives, PEG or Tegaserod and unwilling to discontinue these
             medications at least 2 weeks prior to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2010</study_first_posted>
  <results_first_submitted>April 11, 2012</results_first_submitted>
  <results_first_submitted_qc>July 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2019</results_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Satish Rao</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lubiprostone</title>
          <description>Received 24 mcg of lubiprostone twice a day with meals.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Received placebo twice a day with meals.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lubiprostone</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" spread="11.9"/>
                    <measurement group_id="B2" value="47.3" spread="22.5"/>
                    <measurement group_id="B3" value="43.7" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Methane Production</title>
        <description>Change in the mean area under the curve of the breath hydrogen and methane gas profiles in parts per million, from time 0 to 120 minutes, between baseline versus mean area under the curve at the end of study.</description>
        <time_frame>Baseline and 1 month</time_frame>
        <population>patients who completed the study were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Methane Production</title>
          <description>Change in the mean area under the curve of the breath hydrogen and methane gas profiles in parts per million, from time 0 to 120 minutes, between baseline versus mean area under the curve at the end of study.</description>
          <population>patients who completed the study were analyzed</population>
          <units>parts per million*minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10645" spread="1481"/>
                    <measurement group_id="O2" value="14635" spread="2330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Frequency (Complete Spontaneous Bowel Movements)</title>
        <description>change in mean stool frequency (delta) between baseline week and final week of study</description>
        <time_frame>Baseline and 1 month</time_frame>
        <population>subjects who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Stool Frequency (Complete Spontaneous Bowel Movements)</title>
          <description>change in mean stool frequency (delta) between baseline week and final week of study</description>
          <population>subjects who completed the study</population>
          <units>bowel movements per week</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" spread="0.84"/>
                    <measurement group_id="O2" value="0.85" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in the Colonic Transit Time</title>
        <description>Percentage change of colonic transit time between the baseline colonic transit study and the colonic transit study at the end of study</description>
        <time_frame>Baseline and 1 month</time_frame>
        <population>subjects who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in the Colonic Transit Time</title>
          <description>Percentage change of colonic transit time between the baseline colonic transit study and the colonic transit study at the end of study</description>
          <population>subjects who completed the study</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.06"/>
                    <measurement group_id="O2" value="0.48" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Methane Value</title>
        <description>The peak methane value measured during the baseline breath study will be compared with the peak methane obtained at the end of study breath test</description>
        <time_frame>Baseline and 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Peak Methane Value</title>
          <description>The peak methane value measured during the baseline breath study will be compared with the peak methane obtained at the end of study breath test</description>
          <units>parts per million</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" spread="7.1"/>
                    <measurement group_id="O2" value="70.5" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lubiprostone</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Tightness</sub_title>
                <description>2 subjects experience chest tightness and shortness of breath within one hour of taking the pill.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <description>2 subjects experienced chest tightness and shortness of breath within one hour of taking the pill.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Summers, MD</name_or_title>
      <organization>University of Iowa</organization>
      <phone>319-356-2130</phone>
      <email>robert-summers@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

